Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00927628
Other study ID # ShinjoOI
Secondary ID
Status Completed
Phase N/A
First received June 24, 2009
Last updated June 24, 2009
Start date October 1990
Est. completion date December 2008

Study information

Verified date June 2009
Source Shinjo Ophthalmologic Institute
Contact n/a
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this investigation was to determine the incidence and the factors that cause a reopening of a macular hole (MH) after a surgical closure.


Description:

A reopening of a macular hole (MH) is a well-known complication of successfully closed MHs. Recently, internal limiting membrane (ILM) peeling has become widely used as an adjunctive procedure during MH surgery. The incidence of a reopening of a MH is 0 to 8.6% in eyes in which the ILM was peeled off, and 2 to 16% in which the ILM was not peeled off. Part of the variation in the percentages of reopening was the length of the follow-up period; eyes with longer follow-up periods have higher incidences of reopening.


Recruitment information / eligibility

Status Completed
Enrollment 831
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers
Gender Both
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- patients who underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole

Exclusion Criteria:

- eyes with previous vitreous surgery, cystoid macular edema from any cause, and traumatically-induced MH were excluded.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Procedure:
Vitrectomy
Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.

Locations

Country Name City State
Japan Shinjo Ophthalmologic Institute Miyazaki

Sponsors (1)

Lead Sponsor Collaborator
Shinjo Ophthalmologic Institute

Country where clinical trial is conducted

Japan, 

References & Publications (6)

Duker JS, Wendel R, Patel AC, Puliafito CA. Late re-opening of macular holes after initially successful treatment with vitreous surgery. Ophthalmology. 1994 Aug;101(8):1373-8. — View Citation

Gross JG. Late reopening and spontaneous closure of previously repaired macular holes. Am J Ophthalmol. 2005 Sep;140(3):556-8. — View Citation

Kokame GT. Recurrence of macular holes. Ophthalmology. 1995 Feb;102(2):172-3. — View Citation

Kumagai K, Furukawa M, Ogino N, Larson E, Uemura A. Long-term outcomes of macular hole surgery with triamcinolone acetonide-assisted internal limiting membrane peeling. Retina. 2007 Nov-Dec;27(9):1249-54. — View Citation

Kumagai K, Furukawa M, Ogino N, Uemura A, Demizu S, Larson E. Vitreous surgery with and without internal limiting membrane peeling for macular hole repair. Retina. 2004 Oct;24(5):721-7. — View Citation

Kumagai K, Ogino N, Furukawa M, Larson E, Uemura A. Surgical outcomes for patients who develop macular holes after pars plana vitrectomy. Am J Ophthalmol. 2008 Jun;145(6):1077-80. doi: 10.1016/j.ajo.2008.01.030. Epub 2008 Apr 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary A complete clinical examination including BCVA, slit-lamp biomicroscopy with a contact lens, indirect ophthalmoscopy, and fundus photography were performed post surgery. Patients were examined preoperatively and postoperatively on day one, and at two weeks, and one, three, and six months. Thereafter, they were examined every three to six months. No
See also
  Status Clinical Trial Phase
Terminated NCT04409808 - IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device. N/A
Active, not recruiting NCT04566237 - Objective Measurements of the Opacification of the Lens After Vitrectomy N/A
Completed NCT00532415 - Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy Phase 3
Completed NCT04076072 - Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe N/A
Not yet recruiting NCT03633266 - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Terminated NCT01023009 - Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion
Completed NCT00737022 - Macular Appearance After Diabetic Vitrectomy N/A
Completed NCT02644694 - PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy Phase 1
Completed NCT03902795 - Functional and Morphological Results of Rhegmatogenous Retinal Detachment Treated With Vitrectomy
Completed NCT01319318 - Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy N/A
Not yet recruiting NCT04346095 - Oral Sedation in Vitreoretinal Surgery Phase 4
Completed NCT01159665 - The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) Phase 2
Completed NCT00685490 - Vitrectomy for Branch Retinal Vein Occlusion N/A
Completed NCT05446948 - Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy N/A
Completed NCT05710458 - Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter N/A
Terminated NCT02995746 - Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane N/A
Completed NCT03701542 - The Application of M-charts and Microperimetry for the Assessment of Visual Function in Patients After Vitrectomy Due to the Full Thickness Macular Hole.
Completed NCT00799227 - Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema Phase 2